Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
CYCC's Cash to Debt is ranked higher than
88% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 68.42 vs. CYCC: No Debt )
CYCC' s 10-Year Cash to Debt Range
Min: 1   Max: No Debt
Current: No Debt

Equity to Asset 0.79
CYCC's Equity to Asset is ranked higher than
78% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. CYCC: 0.79 )
CYCC' s 10-Year Equity to Asset Range
Min: -3.51   Max: 0.88
Current: 0.79

-3.51
0.88
Interest Coverage No Debt
CYCC's Interest Coverage is ranked higher than
82% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYCC: No Debt )
CYCC' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: -6.53
M-Score: -1.50
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1658.12
CYCC's Operating margin (%) is ranked higher than
54% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -68.50 vs. CYCC: -1658.12 )
CYCC' s 10-Year Operating margin (%) Range
Min: -66250   Max: -1658.12
Current: -1658.12

-66250
-1658.12
Net-margin (%) -936.62
CYCC's Net-margin (%) is ranked higher than
56% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. CYCC: -936.62 )
CYCC' s 10-Year Net-margin (%) Range
Min: -65040   Max: -936.62
Current: -936.62

-65040
-936.62
ROE (%) -36.23
CYCC's ROE (%) is ranked higher than
66% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. CYCC: -36.23 )
CYCC' s 10-Year ROE (%) Range
Min: -438.16   Max: -36.23
Current: -36.23

-438.16
-36.23
ROA (%) -28.58
CYCC's ROA (%) is ranked higher than
67% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -17.51 vs. CYCC: -28.58 )
CYCC' s 10-Year ROA (%) Range
Min: -135.28   Max: -28.58
Current: -28.58

-135.28
-28.58
ROC (Joel Greenblatt) (%) -6536.00
CYCC's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 876 Companies
in the Global Biotechnology industry.

( Industry Median: -201.33 vs. CYCC: -6536.00 )
CYCC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -11707.75   Max: -427.06
Current: -6536

-11707.75
-427.06
Revenue Growth (%) -18.60
CYCC's Revenue Growth (%) is ranked higher than
66% of the 638 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. CYCC: -18.60 )
CYCC' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 37.5
Current: -18.6

0
37.5
EBITDA Growth (%) -36.10
CYCC's EBITDA Growth (%) is ranked higher than
57% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. CYCC: -36.10 )
CYCC' s 10-Year EBITDA Growth (%) Range
Min: -50.4   Max: 14.1
Current: -36.1

-50.4
14.1
EPS Growth (%) -27.80
CYCC's EPS Growth (%) is ranked higher than
64% of the 636 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. CYCC: -27.80 )
CYCC' s 10-Year EPS Growth (%) Range
Min: -50.8   Max: 19.3
Current: -27.8

-50.8
19.3
» CYCC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CYCC Guru Trades in Q3 2013

Wilbur Ross 116,316 sh (unchged)
» More
Q4 2013

CYCC Guru Trades in Q4 2013

Wilbur Ross 116,316 sh (unchged)
» More
Q1 2014

CYCC Guru Trades in Q1 2014

Wilbur Ross 116,316 sh (unchged)
» More
Q2 2014

CYCC Guru Trades in Q2 2014

Wilbur Ross 116,316 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CYCC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Wilbur Ross 2012-09-30 Reduce -85.71%0.03%$3.14906 - $5.55 $ 3.23-15%116316
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Cyclacel Pharmaceuticals Inc

SymbolPriceYieldDescription
CYCCP7.408.106% Convertible Exchangeable Preferred Stock

Ratios

vs
industry
vs
history
P/B 2.40
CYCC's P/B is ranked higher than
82% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. CYCC: 2.40 )
CYCC' s 10-Year P/B Range
Min: 0.22   Max: 16.44
Current: 2.4

0.22
16.44
P/S 40.40
CYCC's P/S is ranked lower than
62% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 17.18 vs. CYCC: 40.40 )
CYCC' s 10-Year P/S Range
Min: 6.13   Max: 511
Current: 40.4

6.13
511
EV-to-EBIT -2.17
CYCC's EV-to-EBIT is ranked higher than
79% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CYCC: -2.17 )
CYCC' s 10-Year EV-to-EBIT Range
Min: 5.2   Max: 7.7
Current: -2.17

5.2
7.7
Current Ratio 4.79
CYCC's Current Ratio is ranked higher than
71% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. CYCC: 4.79 )
CYCC' s 10-Year Current Ratio Range
Min: 0.96   Max: 12.96
Current: 4.79

0.96
12.96
Quick Ratio 4.79
CYCC's Quick Ratio is ranked higher than
73% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CYCC: 4.79 )
CYCC' s 10-Year Quick Ratio Range
Min: 0.96   Max: 12.96
Current: 4.79

0.96
12.96

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.90
CYCC's Price/Net Cash is ranked higher than
93% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CYCC: 2.90 )
CYCC' s 10-Year Price/Net Cash Range
Min: 0.56   Max: 16.18
Current: 2.9

0.56
16.18
Price/Net Current Asset Value 2.70
CYCC's Price/Net Current Asset Value is ranked higher than
92% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 169.30 vs. CYCC: 2.70 )
CYCC' s 10-Year Price/Net Current Asset Value Range
Min: 0.55   Max: 15.49
Current: 2.7

0.55
15.49
Price/Tangible Book 2.50
CYCC's Price/Tangible Book is ranked higher than
87% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 8.60 vs. CYCC: 2.50 )
CYCC' s 10-Year Price/Tangible Book Range
Min: 0.42   Max: 5.95
Current: 2.5

0.42
5.95
Price/Median PS Value 0.60
CYCC's Price/Median PS Value is ranked higher than
87% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. CYCC: 0.60 )
CYCC' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 6.34
Current: 0.6

0.12
6.34
Earnings Yield (Greenblatt) 630.90
CYCC's Earnings Yield (Greenblatt) is ranked higher than
94% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. CYCC: 630.90 )
CYCC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 12.9   Max: 756.4
Current: 630.9

12.9
756.4
Forward Rate of Return (Yacktman) -106.98
CYCC's Forward Rate of Return (Yacktman) is ranked higher than
55% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. CYCC: -106.98 )
CYCC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 15.9   Max: 16.9
Current: -106.98

15.9
16.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:UXI2.Germany
Cyclacel Pharmaceuticals, Inc., was founded in 1996, and is incorporated Delaware. The Company is a development-stage biopharmaceutical company engaged in the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. The Company develops and commercializes small-molecule drugs that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, particularly those of high unmet medical need. Cyclacel's clinical development priorities are focused on sapacitabine: Acute myeloid leukemia, Myelodysplastic syndromes, and Non-small cell lung cancer.
» More Articles for CYCC

Headlines

Articles On GuruFocus.com
Insider Cluster Buying Reported in Several Companies May 30 2013 
View on CYCC Sep 11 2010 
Cyclacel Pharmaceuticals Inc. Reports Operating Results (10-K/A) May 17 2010 
Cyclacel Pharmaceuticals Inc shares climb 166% in two days Jan 10 2010 
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 

More From Other Websites
Nasdaq stocks posting largest volume increases Aug 21 2014
CYCLACEL PHARMACEUTICALS, INC. Financials Aug 20 2014
Cyclacel Pharmaceuticals Reports Second Quarter 2014 Financial Results Aug 12 2014
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 12 2014
Cyclacel Pharmaceuticals Reports Second Quarter 2014 Financial Results Aug 12 2014
Cyclacel Pharmaceuticals to Release 2014 Second Quarter Financial Results Aug 06 2014
Cyclacel Pharmaceuticals to Release 2014 Second Quarter Financial Results Aug 06 2014
Cyclacel Pharmaceuticals to Present at 9th Annual JMP Securities Healthcare Conference Jun 17 2014
Cyclacel Shapes Sapacitabine's Phase IIb Study For Regulatory Success Jun 10 2014
Cyclacel Pharmaceuticals: The Devil's Advocate Be Damned Jun 04 2014
Cyclacel announces plans for the clinical development of sapacitabine Jun 01 2014
Cyclacel Pharmaceuticals Provides Update on Its Clinical Development Plan of Sapacitabine for... May 31 2014
Cyclacel Pharmaceuticals to Webcast Institutional Investor and Analyst Presentation on Clinical... May 28 2014
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers May 28 2014
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... May 23 2014
Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q1 2014 Results - Earnings Call Transcript May 13 2014
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 13 2014
Cyclacel Pharmaceuticals reports Q1 EPS (25c), consensus (26c) May 13 2014
The Incredible Cyclacel Pharmaceuticals May 06 2014
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Apr 04 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide